Melasma: the full therapy pathway

Most likely because your sunscreen handles UV and melasma is also driven by visible light, which ordinary filters barely touch. The fix is a tinted sunscreen — the iron oxides that create the tint are what block visible light, which is why a tinted SPF 50 beats an untinted SPF 50 here despite the identical number. Heat is a second answer worth knowing about: cooking, saunas and hot cars provoke melasma independently of light.

Honestly: it can fade a great deal, and in some cases — particularly melasma that arrived with a pregnancy — it fades substantially on its own afterwards. But the melanocytes that produced it remain, and they remain primed, so recurrence is the expected behaviour rather than a treatment failure. The realistic aim is control you maintain, not clearance you finish. Anyone promising permanent clearance is describing a product they want to sell.

In the United States, over-the-counter hydroquinone was removed from sale in September 2020 under the CARES Act, when it lost its generally-recognised-as-safe-and-effective status. It remains available on prescription or compounded. In the EU it has long been banned in cosmetic products. The practical consequence matters: if you find hydroquinone being sold over the counter in the US or in an EU cosmetic, that is not a legitimate product — and unregulated skin-lightening creams have repeatedly been found to contain mercury or undeclared potent steroids.

Not as a first move, and only from someone who treats melasma often. Melasma's melanocytes respond to energy by producing more pigment, so the same laser that clears a sun spot can provoke the condition you're treating — rebound is common enough to count as an expected risk rather than a rare complication, and worse in richer skin tones. Current consensus is cautious: low-fluence approaches, by experienced hands, on top of photoprotection and topicals that are already working. A clinic that offers laser as the answer before asking what sunscreen you use is telling you something.

It's licensed for heavy menstrual bleeding and used off-label for melasma, which is routine practice rather than a warning sign. The clotting question is the right one to ask: a 2025 systematic review of randomised trials found no thromboembolic events, which is reassuring — with the honest caveat that trials exclude the people most at risk, which is exactly why a clinician screens your personal and family history before prescribing. That screen is the reason this is a prescription and not a supplement.

Photoprotection and azelaic acid, essentially — and that is genuinely worth doing rather than a consolation prize, since photoprotection is the most effective part of the plan anyway. Hydroquinone, tretinoin, the triple combination and oral tranexamic acid are all avoided in pregnancy. The more useful thing to know is that melasma arriving in pregnancy often fades considerably in the months after, so the right move is frequently protection and patience rather than hunting for something stronger — and specifically not buying hydroquinone from an unregulated source because the legitimate route is closed to you.

Melasma is symmetrical, blotchy and map-like across the cheeks, forehead and upper lip. Sun spots are discrete, scattered and asymmetric.

The two are distinguished mainly by pattern. Melasma forms broad, irregular but symmetrical patches with poorly defined edges, occupying recognisable zones — the cheekbones, forehead, upper lip and jawline — and typically appearing as a mirrored map across the face. Solar lentigines, the flat brown marks of cumulative sun exposure, are discrete, smaller, sharply defined and scattered wherever the sun has fallen most, so they cluster asymmetrically and appear on the hands, chest and shoulders as well. Melasma also fluctuates: it darkens in summer, after sun exposure or in pregnancy, and lightens in winter, whereas a sun spot stays put. Age matters too, since melasma typically begins between the twenties and forties and lentigines accumulate later. The distinction is worth making because the treatments diverge sharply — lentigines respond well and permanently to lasers that can make melasma dramatically worse. If both are present, which is common, they need treating differently rather than together.

Yes. Visible light drives melasma independently of UV, so a clear sunscreen protecting only against ultraviolet leaves a major trigger untouched.

This is the most practically important development in melasma care of recent years. Visible light — the part of the spectrum you can see, particularly the high-energy blue end — stimulates pigment production in richly pigmented skin, and studies have implicated it specifically in melasma and in relapses. Conventional sunscreens are tested and labelled for ultraviolet protection only and are essentially transparent to visible light, which is why people who wear sunscreen diligently still see their melasma darken. What blocks visible light is pigment: iron oxides, alone or with pigmentary titanium dioxide, reflect it, which is the reason tinted sunscreens outperform untinted ones in melasma trials and why an international consensus has described tinted formulations containing iron oxides as the standard for visible-light protection. Practical consequences: choose a tinted sunscreen rather than a clear one, understand that indoor daylight through windows and time outdoors on cloudy days both count, and treat reapplication as part of treatment rather than as sun-holiday behaviour.

Genetically susceptible pigment cells over-responding to three drivers: ultraviolet and visible light, hormones, and inflammation — with light the most modifiable.

Melasma is a disorder of overactive melanocytes in genetically predisposed skin, and three inputs keep them active. Light is the largest: ultraviolet radiation and, importantly, visible light both stimulate pigment production, and visible light in particular has emerged as a major driver of melasma and its relapses, which is why an ordinary transparent sunscreen is insufficient. Hormones are the second, which is why melasma clusters in women, appears or worsens in pregnancy and on combined contraceptives, and is sometimes called the mask of pregnancy. Inflammation is the third and the least appreciated: anything that irritates the skin drives pigment production, which is why aggressive treatment backfires here in a way it does not in other conditions. Newer work also implicates the dermis — altered blood vessels, mast cells and a photo-aged supporting layer — which helps explain why melasma is so persistent and why surface-level treatment alone underperforms. Genetics set susceptibility, and family history is common. Nothing about this is caused by poor skincare or neglect.

Because inflammation itself stimulates pigment production — so any product that leaves skin pink and stinging is feeding the condition it is meant to treat.

This single fact reverses the instincts most people bring from treating acne or ageing. Inflammatory mediators released when skin is irritated activate melanocytes directly, which means a strong peel, an aggressive acid regimen, a retinoid used at a frequency your skin cannot tolerate, or an over-enthusiastic laser all produce a period of visible improvement followed by pigment that is worse than the starting point. It is also why melasma is aggravated by anything abrasive, by hot waxing on the upper lip, by picking, and even by heat itself. The practical rule that follows: in melasma, the gentlest effective regimen beats the strongest tolerable one, which is the opposite of how most actives are approached. If your skin is pink, stinging or peeling, that is not the treatment working; it is a reason to reduce frequency or strength. Two consequences worth holding. Slow progress is expected and is not a reason to escalate. And a clinic offering a dramatic quick result should be regarded with suspicion rather than enthusiasm.

No. Melasma is the pigment condition where lasers most often backfire, with rebound hyperpigmentation and patchy loss of pigment both well documented.

Lasers work beautifully on discrete sun spots and disappoint dangerously on melasma, and the difference catches people out because both are brown patches. The problem is that laser energy absorbed by pigment generates heat and inflammation, and inflammation is melasma's driver — so high-fluence Q-switched treatment in particular has a substantial literature of rebound hyperpigmentation and mottled hypopigmentation, and ablative fractional lasers carry high risk of both. Low-fluence Q-switched protocols and picosecond devices produce less thermal damage and have better records, with picosecond lasers showing fewer post-treatment pigmentation events in deeper skin types, but recurrence rates remain high and results fade. The honest position is that lasers are a considered adjunct in expert hands, on melasma that has already been stabilised medically, never a first move and never a shortcut. Two practical rules: nobody should laser melasma that has not been on treatment and strict photoprotection for months first, and any clinic offering it as a quick fix is describing the mechanism by which it goes wrong.

Mercury, undeclared potent steroids and high-strength hydroquinone are all repeatedly found in them — causing kidney damage, skin thinning and permanent discolouration.

Skin-lightening products sold without full ingredient lists, imported informally or bought online, carry documented and serious risks. Mercury is found in a proportion of them and is absorbed through the skin, causing kidney damage and neurological effects, with regulators in several countries issuing repeated warnings and recalls. Undeclared potent corticosteroids produce fast, convincing lightening followed by skin thinning, visible vessels, steroid-induced acne and a rebound when stopped — and because the user does not know they are applying a steroid, use continues for months. High-strength hydroquinone well above regulated limits causes exogenous ochronosis, the paradoxical blue-black discolouration that is harder to treat than the original melasma. Two rules that cover it. If a cream produces dramatic lightening within days or weeks, that is evidence of an undeclared steroid rather than a discovery. And if there is no full ingredient list in a language you can read, or the product is sold in a plastic pot without a manufacturer, do not put it on your face.

Scrubs, cleansing brushes, at-home peels, high-strength acids, fragrance and anything that stings — subtraction often produces visible improvement on its own.

Because irritation darkens melasma, removing provocations is treatment rather than preparation. Stop: physical scrubs, cleansing brushes and exfoliating mitts; at-home peel kits and high-strength acid toners; anything fragranced, including products described as naturally scented; alcohol-heavy toners; hot water and prolonged steaming; and, importantly, waxing or threading on the upper lip if that is where your pigmentation sits, since the mechanical trauma is a recurring cause of stubborn darkening there. Reduce, rather than stop, anything that leaves you pink — a retinoid used too often, a vitamin C that tingles, an acid used twice weekly when once is tolerable. Then run a bare routine for four weeks: gentle cleanser, plain moisturiser, tinted sunscreen. A meaningful number of people see their pigment stabilise or lighten during that period alone, before any active is reintroduced, which is disconcerting and worth knowing. Reintroduce one thing at a time afterwards, with four weeks between additions, so a reaction can actually be attributed to something.

Azelaic acid, niacinamide, vitamin C, tranexamic acid, cysteamine and thiamidol all have trial support — used one or two at a time, not stacked.

Several over-the-counter actives have genuine evidence, and the constraint is tolerability rather than choice. Azelaic acid is the most versatile: it inhibits tyrosinase, is anti-inflammatory, is well tolerated and is compatible with pregnancy. Niacinamide interferes with pigment transfer and improves barrier function, making it a good partner rather than a soloist. Vitamin C provides antioxidant support and mild tyrosinase inhibition, though low-pH formulations sting and stinging is counterproductive here. Topical tranexamic acid has accumulated real evidence recently and is gentle. Cysteamine and thiamidol are newer entrants with small trials comparing respectably to hydroquinone over twelve weeks, though these are modest studies rather than registration programmes. Kojic acid, arbutin, liquorice extract and glutathione derivatives have thinner support. The rule that matters more than the choice: pick one or two, introduce them slowly, and use them for months. Four brightening serums layered together produce irritation, and irritation darkens melasma faster than any of them lighten it.

Tinted, SPF 50, broad-spectrum, containing iron oxides — the tint is not cosmetic, it is what blocks the visible light that drives melasma.

The specification matters more here than for any other condition. Broad-spectrum SPF 50 covers ultraviolet. Iron oxides, usually appearing as a tint and often alongside pigmentary titanium dioxide, cover visible light, which conventional clear sunscreens transmit almost entirely and which is a major driver of melasma and its relapses. Trials comparing tinted with untinted sunscreen in melasma favour the tinted formulation, and consensus guidance now describes iron-oxide-containing tinted sunscreen as the standard for visible-light protection. Practical requirements: a shade that suits you, since a poor match means it does not get worn; a texture you will reapply; fragrance-free, because irritation darkens melasma. Apply generously each morning and reapply every two to three hours when outdoors or near windows. Two additions that matter more than people expect: a wide-brimmed hat contributes real visible-light protection that no cream matches, and car and office window glass blocks UVB while transmitting UVA and visible light, so indoor and driving exposure counts.

Twelve weeks for partial improvement, and often longer. Anything promising visible clearance in weeks is either irritating your skin or misleading you.

Melasma runs on a slower clock than almost anything else in dermatology, and knowing that in advance is what prevents the escalation that makes it worse. Realistic sequence: no visible change for the first four to six weeks, partial improvement becoming apparent around twelve weeks, and continued gradual improvement over six months and beyond. Even successful treatment produces partial lightening rather than clearance for most people, particularly where pigment is dermal. What speeds nothing but wastes time: switching products every few weeks, which restarts the clock; escalating strength when progress feels slow, which irritates and darkens; and judging by a mirror, since gradual change over months is invisible day to day. What actually helps you judge: photographs in identical conditions — same window, same time, no makeup — taken monthly, which reveal changes a mirror hides. Two additional realities. Progress reverses in summer without rigorous protection, so a flat year is not necessarily a failed regimen. And stopping when improved is what produces relapse.

In defined courses of about three to six months with review and breaks — not continuously, because prolonged use risks exogenous ochronosis.

Hydroquinone remains among the most effective topical treatments for melasma, and its safe use is a matter of duration rather than avoidance. Standard practice is a defined course, commonly three to six months, with clinical review, often cycled with alternatives rather than continued indefinitely, and always alongside rigorous photoprotection without which it substantially underperforms. The reason for the limit is exogenous ochronosis — a paradoxical blue-black discolouration that is harder to treat than the melasma it was applied to, reported after prolonged use, at higher strengths, in sun-exposed and richly pigmented skin, and in some cases after only a few months. Its regulatory status differs by country: prescription-only across much of Europe, available at 2% over the counter in the United States at the time of writing, and a common undeclared ingredient in unregulated imported creams, which is where most harm occurs. Two practical rules: never continue it without review, and if pigment starts turning grey rather than lightening, stop and get it looked at rather than applying more.

At the low doses used, the thromboembolic risk appears very low — but it needs screening for clotting risk factors first and is not for casual use.

Oral tranexamic acid is an antifibrinolytic drug, and its use for melasma is off-label, low-dose and short-course: commonly 250 mg twice daily for eight to twelve weeks, well below the doses used for bleeding disorders. Efficacy evidence is reasonable, with a placebo-controlled trial reporting around a 49% reduction in severity score at three months against 18% on placebo, and meta-analyses supporting benefit. On safety, the reassuring finding is that a large propensity-matched cohort found no significant increase in venous thromboembolism through a year, and pooled trial data reported no thromboembolic events — though broader database analyses have produced conflicting signals and a small residual risk cannot be excluded. What that means practically: this is a treatment requiring structured screening rather than a supplement. It is avoided with personal or family history of clots, thrombophilia, active cancer, smoking with combined contraception, pregnancy, and around surgery or immobility. Reported side effects are usually minor — lighter periods, gastrointestinal upset, headache.

Tinted sunscreen, azelaic acid and niacinamide are the usual safe core. Hydroquinone and retinoids are avoided, and much of it fades after delivery anyway.

Melasma affects a large proportion of pregnancies, and treatment during pregnancy is deliberately conservative — partly for safety and partly because a good deal of it improves after delivery. What is generally considered compatible: broad-spectrum tinted sunscreen, which is the mainstay and does most of the achievable work; azelaic acid, which is widely used in pregnancy and inhibits pigment production; niacinamide; and vitamin C. What is avoided: hydroquinone, which has meaningful systemic absorption and is not used in pregnancy; retinoids in any form; and oral tranexamic acid, which is contraindicated. Chemical peels and laser are deferred. The realistic aim during pregnancy is to prevent worsening rather than to clear, which makes photoprotection the whole strategy — and it matters, because pigment accumulated during nine months of unprotected exposure is what persists afterwards. Two practical points: confirm your specific plan with your obstetric team rather than inferring it, and start protecting early rather than once patches appear.

More active melanocytes respond more readily to light, hormones and inflammation — so the same trigger produces more pigment and it lasts longer.

Melasma is markedly more prevalent in people with intermediate to deeply pigmented skin, particularly those of Hispanic, South and East Asian, Middle Eastern and African descent, and the reason is straightforward: melanocytes in richly pigmented skin are more numerous in their output and more responsive to stimulation. The same ultraviolet exposure, the same hormonal shift and the same inflammatory event produce more pigment and clear more slowly. Visible light matters particularly here, since its pigmenting effect is demonstrated mainly in deeper skin tones and is far less pronounced in pale skin — which is why tinted, iron-oxide-containing sunscreen is more important for you than the general sunscreen advice implies. Two consequences worth acting on. Treatment must be gentler rather than stronger, because post-inflammatory hyperpigmentation on top of melasma is a real and common outcome of aggressive regimens. And any procedure carries higher risk of both rebound darkening and patchy pigment loss, which raises the bar for who should perform one and whether it should be done at all.

When it is solitary, asymmetric, growing, changing colour or shape, or has an irregular border — that needs examining before any pigment treatment.

Melasma is symmetrical, stable in shape, and fluctuates in intensity rather than in outline. A patch behaving otherwise deserves examination rather than a brightening cream. Features that warrant assessment: a solitary lesion with no mirror-image counterpart; asymmetry within the patch itself; growth over weeks or months; more than one colour, particularly black, blue, red or white areas within a brown patch; an irregular or notched border; or a change in surface texture, bleeding or crusting. Lentigo maligna, an early form of melanoma, characteristically presents as a slowly enlarging irregular pigmented patch on sun-damaged facial skin and can be mistaken for a stubborn age spot or melasma for years. Pigmented basal cell carcinoma is another possibility. The action is simple and low-cost: have it looked at before starting treatment, since applying a pigment inhibitor to a lesion that needs diagnosing delays that diagnosis and can partially mask it. Photographs help demonstrate change. Early skin cancers on the face are highly treatable; delayed ones are considerably less so.